Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics

Pharmacogenomics

Volumn 15, Issue 1, 2014, Pages 9-16

  Chen, Shuguang ^a   St Jean, Pamela ^a   Borland, Julie ^a   Song, Ivy ^a   Yeo, Astrid J ^b   Piscitelli, Stephen ^a   Rubio, Justin P ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Dolutegravir; HIV 1; Integrase inhibitor; Pharmacogenetic; Pharmacokinetic; UGT1A1

Indexed keywords

DOLUTEGRAVIR; GLUCURONOSYLTRANSFERASE 1A1;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXPOSURE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACOGENETICS; UGT1A1 GENE;

GENOTYPE; GLUCURONOSYLTRANSFERASE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS;

EID: 84890448894     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.190     Document Type: Article

References (21)

1. Min S, Song I, Borland J et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54(1), 254-258 (2010).
2. Raffi F, Rachlis A, Stellbrink HJ et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381(9868), 735-743 (2013).
3. Eron JJ, Clotet B, Durant J et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J. Infect. Dis. 207(5), 740-748 (2013).
4. Reese MJ, Savina PM, Generaux GT et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab. Dispos. 41(2), 353-361 (2013).
5. Min S, Sloan L, Dejesus E et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 25(14), 1737-1745 (2011).
6. Castellino S, Moss L, Wagner D et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob. Agents Chemother. 57(8), 3536-3546 (2013).
7. Bosma P, Chowdhury JR, Jansen PH. Genetic inheritance of Gilbert's syndrome. Lancet 346(8970), 314-315 (1995).
8. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 9(5), 591-599 (1999).
9. Hazama S, Nagashima A, Kondo H et al. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A128 polymorphism. Cancer Sci. 101(3), 722-727 (2010).
10. Wenning LA, Petry AS, Kost JT et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin. Pharmacol. Ther. 85(6), 623-627 (2009).
11. Trontelj J, Marc J, Zavratnik A, Bogataj M, Mrhar A. Effects of UGT1A128 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol. 67(4), 437-444 (2009).
12. Beutler E, Gelbart T, Demina A. Racialvariability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95(14), 8170-8174 (1998). (Pubitemid 28326085)
13. Horsfall LJ, Zeitlyn D, Tarekegn A et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann. Hum. Genet. 75(2), 236-246 (2011).
14. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333(18), 1171-1175 (1995).
15. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3(3), 136-158 (2003). (Pubitemid 36850156)
16. Song I, Borland J, Chen S et al. Metabolism and drug-drug interaction profile of dolutegravir. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain, 16-18 April 2012.
17. van Lunzen J, Maggiolo F, Arribas JR et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48week results from SPRING-1, a dose-ranging, randomised, Phase 2b trial. Lancet Infect. Dis. 12(2), 111-118 (2012).
18. Chen S, Min SS, Peppercorn A et al. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Pharmacotherapy 32(4), 333-339 (2012).
19. Song I, Borland J, Chen S et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br. J. Clin. Pharmacol. 72(1), 103-108 (2011).
20. Premawardhena A, Fisher CA, Liu YT et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol. Dis. 31(1), 98-101 (2003). (Pubitemid 36802250)
21. clinicaltrials.gov.www.clinicaltrials.gov